1. Home
  2. GAUZ vs CHRS Comparison

GAUZ vs CHRS Comparison

Compare GAUZ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gauzy Ltd. Ordinary Shares

GAUZ

Gauzy Ltd. Ordinary Shares

HOLD

Current Price

$1.46

Market Cap

102.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.33

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAUZ
CHRS
Founded
2009
2010
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.0M
186.0M
IPO Year
2024
2014

Fundamental Metrics

Financial Performance
Metric
GAUZ
CHRS
Price
$1.46
$1.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$11.50
$4.02
AVG Volume (30 Days)
437.0K
861.2K
Earning Date
03-11-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.34
Revenue
$96,810,000.00
$277,728,000.00
Revenue This Year
$22.59
N/A
Revenue Next Year
$47.83
$67.31
P/E Ratio
N/A
$2.53
Revenue Growth
7.87
152.07
52 Week Low
$0.95
$0.71
52 Week High
$13.00
$1.89

Technical Indicators

Market Signals
Indicator
GAUZ
CHRS
Relative Strength Index (RSI) 42.93 48.49
Support Level $0.98 $1.30
Resistance Level $1.57 $1.43
Average True Range (ATR) 0.26 0.08
MACD 0.13 0.01
Stochastic Oscillator 64.23 43.75

Price Performance

Historical Comparison
GAUZ
CHRS

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: